RxDoctor Payments Data

Tracy Warner, DPM

Foot & Ankle Surgery · Indianapolis, INNPI 1457311508

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (40.5%), speaking fees and education — rather than concentrated in one kind of arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 22.8%. Reporting peaked in 2019 at $3,261 and has fallen 66.2% since, to $1,101 in 2025.

$10,187in general payments, 2019–2025

Across 178 payments — averaging $57.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Crossroads Orthopedics, LLC$2K
  • Osteomed LLC$2K
  • Skye Orthobiologics LLC$2K
  • Stryker$969
  • Paratek Pharmaceuticals, Inc.$642
  • Trilliant Surgical LLC.$500
  • plus $3K from 42 others
$1,500in research payments, 2019–2025

Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Skye Orthobiologics LLC$2K

What the payments were for

  • Speaking & faculty fees$3,00029%
  • Food & beverage$4,12240%
  • Education$2,81928%
  • Other$2462%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,187 in reported general payments places this provider in the 70th percentile of 212 foot & ankle surgery providers in Indiana.

See all foot & ankle surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$114,830
Medicare patients
332
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole11$8,400
Ciclopirox38$831
Nabumetone31$535
Mupirocin57$475
Gabapentin43$350
Doxycycline Monohydrate28$294
Duloxetine Hcl24$168
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$107
Azithromycin27$94
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$14$8,40011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 212 foot & ankle surgery providers in Indiana.

Other foot & ankle surgery in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →